TGA updates product warning for GLP-1s

Product warnings across GLP-1 RA class of medications aligned on the potential risk of suicidal ideation  Health professionals are being urged to monitor patients using glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for the emergence or worsening of depression or suicidal thoughts in patients.   The recommendation was made after the Therapeutic Goods Administration (TGA) announced that product warnings for the five GLP-1 RAs